LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announced its cash position and its turnover for the first half 2016.
As of June 30th, 2016, cash and cash equivalents were €32.1 million compared to €29.5 million on June 30th, 2015.
As of June 30th, 2016, cash and cash equivalents were €32.1 million compared to €29.5 million on June 30th, 2015.
